PolyPeptide Group AG (SWX: PPGN)
Health Care · Life Sciences Tools & Services · CH
CHF43.90
-0.45% today · +69.6% 1Y
PolyPeptide Group AG (SWX: PPGN) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $1.76B and employs 1,460 people.
Over the last twelve months the share price has gained 69.6%, trading between 21.80 and 50.10.
Tweenvest scores PolyPeptide Group AG across four factors: quality 67/100, value 40/100, growth 81/100. Its strongest factor is growth.
PPGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.76B
- Revenue (TTM)
- $524.23M
- P/E
- 107.85
- EPS
- 0.44
- Dividend yield
- —
- Beta (5Y)
- 0.97
- 52-week high
- CHF50.10
- 52-week low
- CHF21.80
- Avg volume (3M)
- —
- Shares outstanding
- 33.02M
- Employees
- 1,460
- Next earnings
- —
About PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
- ISIN
- CH1110760852
- Founded
- 1952
- Listed since
- Apr 28, 2021
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| SKAN Group AGSWX: SKAN | $1.91B | CHF70.30 | -0.99% |
| Suzhou Sepax Technologies Co., Ltd.SHSE: 688758 | $1.87B | CN¥30.13 | -7.29% |
| BioLife Solutions, Inc.NasdaqCM: BLFS | $1.82B | $38.61 | +3.51% |
| OneSource Specialty Pharma LimitedNSEI: ONESOURCE | $1.80B | Rs1,508.00 | -5.90% |
| Personalis, Inc.NasdaqGM: PSNL | $1.71B | $16.06 | +0.37% |
| Azenta, Inc.NasdaqGS: AZTA | $1.57B | $36.00 | +0.31% |
| Syngene International LimitedNSEI: SYNGENE | $1.49B | Rs361.30 | -4.59% |
| Indegene LimitedNSEI: INDGN | $1.48B | Rs593.50 | -2.54% |
Figures last refreshed Oct 4, 2026.